newsfilter
← Latest News
CNBC·

Ark Invest analyst says these are two of the firm's favorite genomic revolution plays

In a CNBC interview, Ark Invest analyst Simon Barnett explains the firm's belief in Adaptive Biotechnologies and Invitae.